Pulmonary Arterial Hypertension References

REFERENCES

Doyle RL, McCrory D, Channick RN, et al. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul;126(1)(Suppl 1):63S-71S. doi: 10.1378/chest.126.1_suppl.63S. PMID: 15249495
Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul;126(1)(Suppl 1):35S-62S. doi: 10.1378/chest.126.1_suppl.35S. PMID: 15249494
McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul;126(1)(Suppl Suppl):14S-34S. doi: 10.1378/chest.126.1_suppl.14S. PMID: 15249493
Galiè N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun;43(12)(Suppl S):81S-88S. PMID: 15194183
Nauser TD, Stites SW. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician. 2001 May;63(9):1789-1798. http://www.aafp.org/. PMID: 11352291
McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr;53(17):1573-1619. PMID: 19389575
Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct;30(20):2493-2537. doi: 10.1093/eurheartj/ehp297. PMID: 19713419
Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun;43(Suppl 12):5S-12S. doi: 10.1016/j.jacc.2004.02.037. PMID: 15194173
Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 Dec;25(24):2243-2278. doi: 10.1016/j.ehj.2004.09.014. PMID: 15589643
Channick RN, Rubin LJ. Pulmonary vasculitis and pulmonary hypertension. In: Mason RJ, Murray JF, Broaddus VC, et al. eds. Murray and Nadel’s Textbook of Respiratory Medicine. 4th ed. Philadelphia: Elsevier Saunders; 2005:1465-1474
MedWormhttp://www.medworm.com/rss/index.php/Cardiology/7/http://www.medworm.com/rss/medicalfeeds/specialities/Cardiology.xml
MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
MedWormhttp://www.medworm.com/rss/index.php/Respiratory-Medicine/40/http://www.medworm.com/rss/medicalfeeds/specialities/Respiratory-Medicine.xml
Medworm - Pulmonary Hypertensionhttp://www.medworm.com/rss/medicalfeeds/conditions/Pulmonary-Hypertension.xml
McCrory DC, Coeytaux RR, Schmit KM, et al. Pulmonary Arterial Hypertension: Screening, Management, and Treatment. Comparative Effectiveness Review No. 117. AHRQ. Publication No. 13-EHC087-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2013 Apr. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0056718/pdf/TOC.pdf. Accessed 23 Apr 2014.
Hopkins W, Rubin LJ. Treatment of pulmonary hypertension in adults. UpToDate. http://www.uptodate.com/. Feb 2019.
Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec;62(Suppl 25):D60-72. doi: 10.1016/j.jacc.2013.10.031. PMID: 24355643
Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec;62(Suppl 25):D34-41. http://content.onlinejacc.org/data/Journals/JAC/929484/10029.pdf. Accessed 17 Jul 2014. PMID: 24355639
US Food and Drug Administration. Press Announcements: FDA Approves Opsumit to treat pulmonary arterial hypertension. US Food and Drug Administration website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm371362.htm. Oct 2013.
Patel T, McKeage K. Macitentan: first global approval. Drugs. 2014 Jan;74(1):127-133. doi: 10.1007/s40265-013-0156-6. PMID: 24297706
Galiè N, Humbert M, Vachiery JL, et al; Authors/Task Force Members. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Accessed 26 Nov 2015. PMID: 26320113
Kamangar N. Secondary pulmonary hypertension treatment & management. eMedicine. http://emedicine.medscape.com/article/303098-treatment. Oct 2015.
McLaughlin VV, Channick R, Chin K, et al. Effect of selexipag on mobidity/mortality in pulmonary arterial hypertension: results of GRIPHON study. J Am Coll Cardiol. 2015 Dec;373(26):2522-2533. doi:10.1016/S0735-1097(15)61538-8. PMID: 26699168
Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014 Aug;146(2):449-475. doi: 10.1378/chest.14-0793. PMID: 24937180
Frost A, Badesch D, Giibs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01904-2018. PMID: 30545972
Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01889-2018. PMID: 30545971
Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.02148-2018. PMID: 30552088
Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01906-2018. PMID: 30545979
Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01887-2018. PMID: 30545970
Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019 Mar;155(3):565-586. doi: 10.1016/j.chest.2018.11.030. PMID: 30660783
Rubin LJ, Hopkins W. Classification and prognosis of pulmonary hypertension in adults. UptoDate. http://www.uptodate.com/. Feb 2019.
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01913-2018. PMID: 30545968
Condon DF, Nickel NP, Anderson R, et al. The 6th world symposium on pulmonary hypertension: what’s old is new. F1000Res. 2019 Jun;8:F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1. PMID: 31249672.
Hirani N, Brunner NW, Kapasi A, et al. Canadian Cardiovascular Society/Canadian Thoracic Society position statement on pulmonary hypertension. Can J Cardiol. 2020 Jul;36(7):977-992. doi: 10.1016/j.cjca.2019.11.041. PMID: 32682511
Hopkins W, Rubin LJ. Treatment and prognosis of pulmonary arterial hypertension in adults (group 1). UpToDate. https://www.uptodate.com. 24 Jan 2020.
Hopkins W, Rubin LJ. Treatment of pulmonary arterial hypertension (group 1) in adults: pulmonary hypertension-specific therapy. UpToDate. https://www.uptodate.com. 20 Aug 2020.
Rubin LJ, Hopkins W. The epidemiology and pathogenesis of pulmonary arterial hypertension. UpToDate. https://www.uptodate.com. 29 Feb 2020.
Sitbon O, Cottin V, Canuet M, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J. 2020 Sep;56(3):2000673. doi: 10.1183/13993003.00673-2020. PMID: 32350101
Thomas CA, Anderson RJ, Condon DF, et al. Diagnosis and management of pulmonary hypertension in the modern era: insights from the 6th world symposium. Pulm Ther. 2020 Jun;6(1):9-22. doi: 10.1007/s41030-019-00105-5. PMID: 32048239

Management of MDROs in the ICU and the role of newer antimicrobial agents

Prof. David Paterson, 30 Mar 2021

Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.

Timely treatment of patients at risk for severe COVID-19 prevents severe outcomes

Dr. Asok Kurup, Dr. Alex Soriano, 31 Oct 2022

Despite widespread uptake of vaccinations, COVID-19 remains a serious health issue for high-risk patients, owing to the emergence of new variants of concern (VOCs), waning immunity, and breakthrough infections.

At a recent symposium in Singapore, esteemed experts Dr Asok Kurup, Consultant Infectious Diseases Physician at Mount Elizabeth Medical Centre, Singapore, and Dr Alex Soriano, Head of Infectious Diseases Department, Hospital Clínic of Barcelona and Assistant Professor, University of Barcelona, Spain, gave insights on the evolution of global trends since the start of the COVID-19 pandemic and discussed key challenges in managing high-risk patients with COVID-19 in the ICU. They also highlighted early treatment strategies to minimize the burden of COVID-19 on healthcare systems.

Mepolizumab: Targeting eosinophils in severe asthma with precision medicine

Pearl Toh, 16 Sep 2020

Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.